CeloNova BioSciences today announced that the company is submitting to its European Notified Body a request for approval of its new, lime green, 2800 micron size Embozene(TM) Microsphere.
Embozene(TM) Color-Advanced Microspheres are spherical embolics approved in Europe for the treatment of liver cancer, uterine fibroids, tumors of the head, neck, torso, and skeletal system; for bleeding and trauma, including nosebleeds; and for reducing the amount of bleeding before any surgery other than in the central nervous system.
"Physicians use microspheres to stop bleeding before a procedure, such as the removal of a tumor, but no one to date has been able to create a microsphere that fits larger blood vessels," said Thomas A. Gordy, President and Chief Executive Officer of CeloNova. "We developed this 2800 micron size to meet the needs of interventional radiologists."
In Europe, CeloNova currently offers 10 highly calibrated sizes of Embozene(TM) Microspheres in range from 40 microns to 1300 microns, making it one of the most versatile embolics in the market. The new 2800 micron size will be the largest microsphere available to physicians.
Study reveals breakthrough in non-invasive detection of endometrial cancer